Literature DB >> 21389741

Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy.

Andrew C T Fok1, Poemen P M Chan, Dennis S C Lam, Timothy Y Y Lai.   

Abstract

BACKGROUND: To evaluate risk factors for the recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy (CSC).
METHODS: Retrospective review of untreated CSC patients with a follow-up of ≥3 years. Patient demographics, visual outcome and risk factors for the recurrence of CSC were analyzed.
RESULTS: Seventy-three eyes of 73 patients were included, and the mean age was 44.6 years. At baseline, the mean logMAR best corrected visual acuity (BCVA) was 0.30. After a mean follow-up of 72 months, the mean final logMAR BCVA was 0.32. The difference between the final and baseline BCVAs was not statistically significant (p = 0.79). At the last follow-up, 9 (12.3%) eyes showed improved vision of ≥2 lines, and 12 (16.4%) showed a worsening of ≥2 lines. During follow-up, 38 (52.1%) patients experienced ≥1 episode of CSC recurrence. Multivariate Cox regression analysis showed that patients with a history of psychiatric illness (adjustment disorder and depression) were associated with an increased risk of CSC recurrence (hazard ratio = 3.5, p = 0.011).
CONCLUSIONS: The long-term visual prognosis of CSC is fair without treatment, and a significant proportion of patients developed recurrence of CSC. A history of psychiatric illness is associated with an increased risk of CSC recurrence.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21389741     DOI: 10.1159/000324599

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  26 in total

1.  The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.

Authors:  A Ozkaya; Z Alkin; M Ozveren; A T Yazici; M Taskapili
Journal:  Eye (Lond)       Date:  2016-04-22       Impact factor: 3.775

2.  A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.

Authors:  Lijun Zhou; Victor Chong; Kunbei Lai; Chuangxin Huang; Fabao Xu; Yajun Gong; Maimaitiaili Youlidaxi; Tao Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

3.  Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Hasan Gunes; Gokhan Demir
Journal:  Lasers Med Sci       Date:  2021-01-07       Impact factor: 3.161

4.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

5.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

6.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

7.  Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.

Authors:  Mengyang Li; Jinfeng Qu; Zhiqiao Liang; Jiyang Tang; Jie Hu; Yuou Yao; Enzhong Jin; Xiaoxin Li; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-13       Impact factor: 3.117

Review 8.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

9.  Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.

Authors:  Olesya Zavoloka; Pavlo Bezditko; Irina Lahorzhevska; Darya Zubkova; Yevgeniya Ilyina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-16       Impact factor: 3.117

Review 10.  Central Serous Chorioretinopathy and Personality Characteristics: A Systematic Review of Scientific Evidence over the Last 10 Years (2010 to 2020).

Authors:  Giovanni Genovese; Alessandro Meduri; Maria Rosaria Anna Muscatello; Sebastiano Gangemi; Clemente Cedro; Antonio Bruno; Pasquale Aragona; Gianluca Pandolfo
Journal:  Medicina (Kaunas)       Date:  2021-06-16       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.